Clinical Trials Logo

Clinical Trial Summary

This research trial studies genetic profiles in blood and tumor samples from patients with estrogen receptor positive and HER2 negative breast cancer that has spread to other places in the body who are receiving palbociclib and endocrine therapy. Examining the genetic changes associated with the cancer and comparing the genetic material from the cancer tissue with the genetic material found in the blood may help doctors to develop customized treatment for breast cancer.


Clinical Trial Description

PRIMARY OBJECTIVES: I. To identify novel genomic variants and pathways associated with baseline, as well as the change in serum thymidine kinase (TK1) levels (measured pre-registration, after two cycles, and at disease progression) among women with advanced hormone receptor (HR) positive breast cancer treated with palbociclib and endocrine therapy (ET). SECONDARY OBJECTIVES: I. To generate patient derived xenograft (PDX)s and organoids from tumor biopsies obtained at pre-registration, at 2 months, and at disease progression, to test novel endocrine therapy combinations. (PDX Aim) II. To test whether PDX engraftment is associated with progression free survival. (PDX Aim) Sequencing Aims III. to describe changes in the genomic landscape of HR-positive HER2-negative advanced breast cancer by comparing sequencing data (deoxyribonucleic acid [DNA] and ribonucleic acid [RNA]) from preregistration archival breast primary tumors (when available), with tumor biopsies obtained preregistration, after two months on study, and at disease progression on palbociclib and ET. IV. To evaluate whether genomic variants and pathways (measured using DNA and RNA sequencing at pre-registration and after two months of treatment) are associated with 1) PFS; 2) baseline and changes in serum TK1. (Sequencing Aim) V. To tabulate the number of patients who have targetable mutations found in the preregistration tumor biopsy and to record their subsequent treatment regimen following progression on palbociclib and ET. (Sequencing Aim) VI. To compare and contrast the actionable genomic alterations found in cfDNA or CTC derived DNA that are not found in tumor tissue. (Sequencing Aim) VII. To assess whether genetic alterations known to be associated with endocrine monotherapy resistance are seen in circulating tumor- DNA (ctDNA) and circulating tumor cell (CTC) derived DNA. (Sequencing Aim) VIII.To determine whether use of a 3D micro cancer model, combined with sequencing data from tumor biopsies, ctDNA and PDXs collected at the time of disease progression, can be used to personalize future treatment options for PROMISE participants. (Sequencing Aim) IX. To compare the changes in Ki67 levels (by immunohistochemistry [IHC]) and serum TK1 levels after 2 months of treatment. (Proliferative biomarker aim) X. To assess whether the change in Ki67 and serum TK1 levels after 2 months of treatment with palbociclib and ET is associated with progression free survival (PFS) outcomes. (Proliferative biomarker aim) XI. To assess whether high baseline serum TK1 levels (> 200 Du/L) are associated with PFS outcomes. (Proliferative biomarker aim) XII. To assess whether an increase in TK1 between 2 months and 12 months is associated with PFS. (Proliferative biomarker aim) XIII. To assess the change in EMT marker expression (e.g. Vimentin, SLUG and E-cadherin) and serum TK1 after two months of treatment with palbociclib and ET. (EMT aim) XIV. To determine the association between the expression of EMT markers and Ki67 levels after two months of treatment with palbociclib and ET. (EMT aim) XV. To determine the association between the expression of EMT markers after two months of treatment with palbociclib and ET, and PFS outcomes. (EMT aim) XVI. To assess whether there is a change in the level of tumor infiltrating lymphocytes (TILs) observed in archival tumor, at pre-registration, at 2 months, and at disease progression on palbociclib and ET. (Immune aim) XVII. To assess the change in TILs (including CD8, PD-L1, and FOXP3) after 2 months of treatment with palbociclib and ET. (Immune aim) XVIII. To assess the association between TILs and serum TK1 levels at preregistration, at 2 months, and at disease progression on palbociclib and ET. (Immune aim) XIX. To characterize and evaluate changes in the immune landscape of HR+ HER2 -MBC using serial biopsies obtained pre-registration, at 2 months, and at disease progression (as well as archived primary tumor when available) using digital spatial profiling (DSP) (NanoString GeoMx platform) . (Immune aim) XX. To assess, by use of mass cytometry (CyTOF), whether i) peripheral blood immune markers obtained pretreatment are associated with either TK1 or PFS and ii) whether the changes in peripheral blood immune markers after 2 cycles of treatment are associated with changes in serum TK1 levels. (Immune aim) XXI. To discover putative mechanistic connections underlying bacteria-drug interactions in all patients. (Microbiome aim) XXII. To identify the biomolecular features within the gut (stool) microbiome and its association with the pharmacokinetics and pharmacodynamics of letrozole and palbociclib. (Microbiome aim) XXIII. To discover novel predictive biomarkers of resistance to CDK4/6i and ET and/or to find biomarkers that add additional predictive power to other promising biomarkers such as TK1 by performing the following: (Metabolic, proteomic and lipidomic aim) XXIV. A metabolomics analysis (>5,000 metabolites sampled through untargeted mass spectrometry at Metabolon) of paired serum samples obtained pre-registration and after 2 months on palbociclib and ET. XXIVa. An Olink-based cytokines panel (Explore panel of 1,536 proteins) of paired serum samples obtained pre-registration and after 2 months on palbociclib and ET. XXIVb. A lipidomics analysis (platform TBC) of paired serum samples obtained pre-registration and after 2 months on palbociclib and ET. XXV. To correlate the changes in the metabolites, cytokines and lipids to the preregistration genomic tumor characteristics, serial Ki67 levels and PFS outcomes. (Metabolic, proteomic and lipidomic aim) XXVI. To assess the change in serum TK1 levels after 2 months, and at disease progression, on palbociclib and ET, and its association with the preregistration CD44high/CD24/low/ERlow cancer stem cell-like phenotype, including the following: total and phosphorylated AURKA, breast cancer stemness biomarkers (CD44, CD24, ALDH1) EMT transcription factors (SMAD5, SOX2), cyclin E, cyclin A and phosphorylated Retinoblastoma (Rb). (Other aim) XXVII. To examine shifts in the populations of epithelial like CTCs and stem cell like CTCs during the course of endocrine therapy with palbociclib. (Other aim) XXVIII. To assess CTC expression of ER, HER2, and other markers of endocrine resistance. (Other aim) OUTLINE: Patents undergo collection of blood and stool samples at baseline, 7 days after letrozole monotherapy treatment, and at completion of each cycle, urine samples at baseline and completion of each cycle, and saliva samples at baseline. Patients also undergo collection of blood and urine samples at disease progression. Biopsy samples are analyzed for genetic profile via genome sequencing and ribonucleic acid (RNA) sequencing. Biopsy samples are also used for the generation of xenograft mice model. After completion of study, patients are followed up every 6 months for 7 years. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03281902
Study type Observational
Source Mayo Clinic
Contact
Status Active, not recruiting
Phase
Start date November 13, 2017
Completion date December 1, 2024

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04052555 - Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer Phase 1
Recruiting NCT04521764 - A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer Phase 1
Completed NCT00100750 - Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer Phase 1/Phase 2
Suspended NCT03737695 - Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer
Active, not recruiting NCT02595905 - Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases Phase 2
Terminated NCT02149173 - F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy N/A
Completed NCT00390455 - Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive Phase 3
Recruiting NCT03213041 - Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer Phase 2
Not yet recruiting NCT04529044 - 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer Phase 2
Completed NCT00699491 - Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer Phase 1/Phase 2
Completed NCT03364348 - 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer Phase 1
Terminated NCT01149356 - RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer Phase 1
Completed NCT01964924 - Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer Phase 2
Completed NCT00785291 - Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Phase 3
Terminated NCT02370264 - Questionnaires in Identifying Upper Extremity Function and Quality of Life After Treatment in Patients With Breast Cancer N/A
Terminated NCT00998738 - Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer Phase 3
Terminated NCT01071564 - RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery Phase 1
Active, not recruiting NCT00520975 - First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU Phase 3
Completed NCT01251874 - Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer Phase 1
Recruiting NCT03987555 - Paclitaxel Therapeutic Drug Monitoring in Cancer Patients